Similar articles

• Gonadotropin-releasing hormone agonists for the preservation of ovarian function during chemotherapy.

  Tomao F, Benedetti Panici P, Tomao S. Tomao F, et al. J Clin Oncol. 2012 Sep 10;30(26):3310-1; author reply 3312-3. doi: 10.1200/JCO.2012.42.2436. Epub 2012 May 29. J Clin Oncol. 2012. PMID: 22649128 No abstract available.
• Gonadotropin-releasing hormone agonist for preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.

  Blumenfeld Z. Blumenfeld Z. J Clin Oncol. 2012 Sep 10;30(26):3310; author reply 3312-3. doi: 10.1200/JCO.2012.41.8467. Epub 2012 May 29. J Clin Oncol. 2012. PMID: 22649145 No abstract available.
• Ovarian suppression for prevention of premature menopause and infertility: empty promise or effective therapy?

  Partridge AH. Partridge AH. J Clin Oncol. 2012 Feb 10;30(5):479-81. doi: 10.1200/JCO.2011.37.9883. Epub 2012 Jan 9. J Clin Oncol. 2012. PMID: 22231046 No abstract available.
• Overview of luteinizing hormone-releasing hormone agonists in early breast cancer-benefits of reversible ovarian ablation.

  Jonat W. Jonat W. Breast Cancer Res Treat. 2002 Oct;75 Suppl 1:S23-6: discussion S33-5. doi: 10.1023/a:1020309715942. Breast Cancer Res Treat. 2002. PMID: 12353820 Review.
• [Role of GnRH agonists in preserving female fertility].

  Thomin A, Torre A, Daraï É, Chabbert-Buffet N. Thomin A, et al. J Gynecol Obstet Biol Reprod (Paris). 2014 Apr;43(4):267-74. doi: 10.1016/j.jgyn.2013.11.001. Epub 2013 Dec 8. J Gynecol Obstet Biol Reprod (Paris). 2014. PMID: 24321862 Review. French.